O-(3,5-diflourobenzyl)hydroxylamine hydrochloride | 796060-93-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: O-(3,5-diflourobenzyl)hydroxylamine hydrochloride
• 英文别名: O-(3,5-difluorobenzyl)hydroxylamine hydrochloride；o-(3,5-Difluorobenzyl)hydroxylamine hydrochloride；O-[(3,5-difluorophenyl)methyl]hydroxylamine;hydrochloride
• CAS: 796060-93-0
• 化学式: C₇H₇F₂NO*ClH
• 分子量: 195.596
• InChiKey: CKGIITMBWCAFOY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.78
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  35.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  O-(3,5-diflourobenzyl)hydroxylamine hydrochloride 、 (16alpha,17beta)-3,16,17-三羟基雌甾-1,3,5(10)-三烯-6-酮 在 poly(4-vinylpyridine) 作用下， 以 甲醇 为溶剂， 反应 48.0h， 以86%的产率得到6-(3,5-difluorobenzyloxy)iminoestriol
  参考文献：
  名称：

  [EN] ESTRATRIENE DERIVATIVES
  [FR] DERIVES D'ESTRATRIENE

  摘要：

  调节间叶细胞功能的化合物和方法，例如平滑肌和成纤维细胞增殖或细胞因子表达，以及治疗与间叶细胞功能相关的疾病，例如与哮喘相关的气道高反应性。这些化合物还抑制炎症。这些化合物是一类雌三烯衍生物，包括各种2-甲氧基雌二醇衍生物，其中包括A组，包括在2-、6-或17-位置有取代芳香基团。

  公开号：

  WO2004101595A1
• 作为产物：
  描述：

  3,5-二氟苄醇 在 盐酸 、 偶氮二甲酸二异丙酯 、 一水合肼 、 三苯基膦 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 3.5h， 生成 O-(3,5-diflourobenzyl)hydroxylamine hydrochloride
  参考文献：
  名称：

  O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1

  摘要：

  Indoleamine 2,3-dioxygenase-1 (IDO1) is a promising therapeutic target for the treatment of cancer, chronic viral infections, and other diseases characterized by pathological immune suppression. Recently important advances have been made in understanding IDO1's catalytic mechanism. Although much remains to be discovered, there is strong evidence that the mechanism proceeds through a heme-iron bound alkylperoxy transition or intermediate state. Accordingly, we explored stable structural mimics of the alkylperoxy species and provide evidence that such structures do mimic the alkylperoxy transition or intermediate state. We discovered that O-benzylhydroxylamine, a commercially available compound, is a. potent sub-micromolar inhibitor of IDO1. Structure activity studies of over forty derivatives of O-benzylhydroxylamine led to further improvement in inhibitor potency, particularly with the addition of halogen atoms to the meta position of the aromatic ring. The most potent derivatives and the lead, O-benzylhydroxylamine, have high ligand efficiency values, which are considered an important criterion for successful drug development. Notably, two of the most potent compounds demonstrated nanomolar-level cell-based potency and limited toxicity. The combination of the simplicity of the structures of these compounds and their excellent cellular activity makes them quite attractive for biological exploration of IDO1 function and antitumor therapeutic applications. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.12.028

文献信息

• Estratriene Derivatives
  申请人：Stewart George Alastair

  公开号：US20070275935A1

  公开（公告）日：2007-11-29

  Compounds and methods for modulating mesenchymal cell function, for instance smooth muscle and fibroblast proliferation or cytokine expression, and for treating conditions associated with mesenchymal cell function, for instance airway hyperresponsiveness associated with asthma. The compounds also suppress inflammation. The compounds are a class of estratriene derivates, and includes various derivatives of 2-methoxyestradiol comprising a group A, including a substituted aromatic substituent in the 2-, 6- or 17-position.

  化合物和方法用于调节间充质细胞功能，例如平滑肌和成纤维细胞增殖或细胞因子表达，并用于治疗与间充质细胞功能相关的疾病，例如与哮喘相关的气道过度反应。这些化合物还可抑制炎症。这些化合物是一类雌三烯衍生物，包括2-甲氧基雌二醇的各种衍生物，其中包括A组，包括2-，6-或17-位取代芳香基取代物。
• NON-STEROIDAL COMPOUNDS
  申请人：Stewart Alastair

  公开号：US20120046255A1

  公开（公告）日：2012-02-23

  The present invention relates to non-steroidal compounds useful in the treatment of inflammatory conditions and pharmaceutical compositions comprising them. A representative example of these compounds is

  本发明涉及非甾体化合物，可用于治疗炎症状况，以及包含它们的制药组合物。这些化合物的代表性例子是：
• US8536157B2
  申请人：——

  公开号：US8536157B2

  公开（公告）日：2013-09-17
• [EN] NON-STEROIDAL COMPOUNDS<br/>[FR] COMPOSÉS NON STÉROÏDIENS
  申请人：CRYPTOPHARMA PTY LTD

  公开号：WO2008124878A1

  公开（公告）日：2008-10-23

  [EN] The present invention relates to non-steroidal compounds useful in the treatment of inflammatory conditions and pharmaceutical compositions comprising them. A representative example of these compounds is formula (III).
  [FR] L'invention concerne des composés non stéroïdiens pouvant servir au traitement d'états inflammatoires et des compositions pharmaceutiques les contenant. Un exemple représentatif de ces composés est de formule (I).
• O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1
  作者：William P. Malachowski、Maria Winters、James B. DuHadaway、Ariel Lewis-Ballester、Shorouk Badir、Jenny Wai、Maisha Rahman、Eesha Sheikh、Judith M. LaLonde、Syun-Ru Yeh、George C. Prendergast、Alexander J. Muller

  DOI：10.1016/j.ejmech.2015.12.028

  日期：2016.1

  Indoleamine 2,3-dioxygenase-1 (IDO1) is a promising therapeutic target for the treatment of cancer, chronic viral infections, and other diseases characterized by pathological immune suppression. Recently important advances have been made in understanding IDO1's catalytic mechanism. Although much remains to be discovered, there is strong evidence that the mechanism proceeds through a heme-iron bound alkylperoxy transition or intermediate state. Accordingly, we explored stable structural mimics of the alkylperoxy species and provide evidence that such structures do mimic the alkylperoxy transition or intermediate state. We discovered that O-benzylhydroxylamine, a commercially available compound, is a. potent sub-micromolar inhibitor of IDO1. Structure activity studies of over forty derivatives of O-benzylhydroxylamine led to further improvement in inhibitor potency, particularly with the addition of halogen atoms to the meta position of the aromatic ring. The most potent derivatives and the lead, O-benzylhydroxylamine, have high ligand efficiency values, which are considered an important criterion for successful drug development. Notably, two of the most potent compounds demonstrated nanomolar-level cell-based potency and limited toxicity. The combination of the simplicity of the structures of these compounds and their excellent cellular activity makes them quite attractive for biological exploration of IDO1 function and antitumor therapeutic applications. (C) 2015 Elsevier Masson SAS. All rights reserved.